Podcasts about md phd

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

“Toxins are everywhere — in our food, water, and air. They damage our mitochondria, disrupt metabolism, and open the door to disease.” —Dr. Richard ChengIn this episode of the Real Health Podcast, Ron Hunninghake, MD, sits down with Richard Cheng, MD, PhD, ABAARM — physician, researcher, and editor of Orthomolecular Medicine News Service — to explore how environmental toxins and mitochondrial dysfunction are driving today's rise in chronic illness and cancer.Dr. Cheng shares how decades of research have revealed the link between toxins, aging, and cancer and why supporting mitochondrial health and reducing environmental exposure may be one of the most effective preventive strategies in modern medicine.

This episode is for you if you're having surgery or if you have a loved one undergoing surgery soon. We are going to learn how to optimize health prior to surgery for better recovery and better outcomes! Approximately 15 million Americans undergo some type of surgery each year, according to the American College of Surgeons.Rebecca Knackstedt is a board-certified plastic surgeon specializing in implant-based and microsurgical breast reconstruction. She is currently an Assistant Professor in Plastic and Reconstructive surgery at Duke University. Rebecca completed her MD/PhD at Medical University of South Carolina where her PhD thesis focused on Vitamin D and inflammation. She pursued an integrated plastic surgery residency and microsurgery fellowship at the Cleveland Clinic during which she also became certified in Functional Medicine. Her research interests are prehabilitation for breast cancer, particularly for women undergoing neoadjuvant chemotherapy.We learn:Prehabilitation is essential for optimizing health before surgerySurgeons often lack training in nutrition and pre-surgical careNutrition plays a crucial role in recovery and healing post-surgeryAlcohol consumption can negatively impact surgical outcomesProtein intake is vital for healing after surgeryPatients should be proactive in preparing for their surgical consultationsVitamin D levels are often overlooked but should be monitored carefullyMuscle strength is predictive of surgical recovery outcomesAvoid Boost as a nutrition supplement post-surgerySleep hygiene is important for overall health and recoveryConnect with Dr. Knackstedt:https://www.instagram.com/surgical_recovery/ https://www.youtube.com/@Surgical_Recovery⁠#surgeryrecovery #recovery #surgerylife #health #surgicalaftercare #rehabilitation #physiotherapy  #physicaltherapy

Harvard MD/PhD Nick Norwitz reversed ulcerative colitis, lowered cholesterol with Oreos, and now exposes the cracks in modern medicine. This episode is a masterclass in metabolic rebellion and curiosity.Join the Kiltz Health Certification Course here: 50% DISCOUNT until 10/8/2025: https://buy.stripe.com/fZuaEYbJaeCp4Df2OY0480xJoin the Kiltz Mighty Tribe - It's free: https://kiltz-mighty-tribe.mn.co/0:00 – Nick's medical legacy and why he chose medicine 4:12 – Ulcerative colitis diagnosis and desperation-driven healing 8:45 – Ketogenic diet leads to full remission 12:30 – Why modern medicine fails chronic disease patients 16:05 – Incentives, pharma, and the business of healthcare 20:40 – Why RCTs don't reflect real-world healing 25:10 – Nutrition education gaps in med school 30:00 – GLP-1s, statins, and lifestyle vs. pharma 35:45 – Nick's grocery cart: what he actually eats 41:20 – Red meat and cancer myths 46:00 – The Oreo experiment: lowering LDL with cookies 50:30 – Empowering patients to lead their own health journey 54:00 – “Stay Curious”: Nick's mantra and tattoo 58:00 – Where to follow Nick Norwitz and final reflections

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

In today's episode, we had the pleasure of speaking with Anne Chiang, MD, PhD, and Stephen Liu, MD, about the FDA approval of lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after frontline induction therapy with atezolizumab or atezolizumab and hyaluronidase, carboplatin, and etoposide. Chiang is an associate professor of medicine in the Section of Medical Oncology and the associate cancer center director of Clinical Initiatives at the Yale School of Medicine in New Haven, Connecticut. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Drs Chiang and Liu discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 IMforte trial (NCT05091567), and how the addition of this regimen in the ES-SCLC treatment paradigm may affect clinical practice.

Brett Owens, MD, Professor of Orthopaedic Surgery at the Brown University Alpert Medical School in Providence, Rhode Island and Editor-in-Chief of the American Journal of Sports Medicine, and Miho Tanaka, MD, PhD, Director of the Women's Sports Medicine Program at the Massachusetts General Hospital, Associate Professor of Orthopaedic Surgery at Harvard Medical School, and Associate Editor at the American Journal of Sports Medicine, discuss the exciting future of AJSM, challenges in patellofemoral care, women's sports medicine, their secret and not-so-secret talents, and more.

Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

What does it truly mean to be successful in medicine? This episode features Dr. Valentin Calu, an Associate Professor of Surgery from Romania, who shares his profound journey from a near-fatal plane crash during an organ harvest mission to his powerful return to the operating room. Discover a unique perspective on surgical leadership, the importance of mentorship, and the deep personal growth required to thrive in high-stakes medical environments. Dr. Calu provides his definitive "Prescription for Success," a ten-point framework built on discipline, team value, and self-awareness. This conversation is essential for any medical professional seeking to build a resilient, impactful, and fulfilling career beyond clinical skill alone. Key Topics Discussed: The long pathway to becoming a surgeon and the transformational journey of residency. Overcoming a life-altering trauma and the mental shift from being a caregiver to a patient. Redefining success as a combination of calling, discipline, and consistency. The critical importance of humility, teamwork, and leading by example in the operating room. Strategies for maintaining physical health to fuel mental clarity and surgical performance. The philosophy of leaving a legacy through teaching and inspiring the next generation. Practical advice on time management, prioritization, and achieving work-life balance. Featured Expert: Dr. Valentin Calu is an Associate Professor of Surgery and Pharmacy at Carol Davila University in Bucharest, Romania. He is a respected HPB surgeon and a passionate educator dedicated to surgical excellence and mentorship. Relevant Keywords: surgeon leadership, physician burnout, medical career development, surgical residency, overcoming adversity, medical mentorship, work life balance for doctors, patient safety, operating room team, clinical resilience, medical legacy, healthcare leadership, physician coaching, surgical training, professional development for physicians, medical education, doctor patient relationship, hospital culture, success in medicine. Subscribe for more conversations with exceptional medical professionals on leadership, career transition, and personal growth.

Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.

Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.

Dr. John Crary is a MD/PhD and board-certified neuropathologist at the Icahn School of Medicine at Mount Sinai. Dr. Crary is a leading physician-scientist whose work has redefined how brain diseases are diagnosed, from primary age-related tauopathy (PART) to chronic traumatic encephalopathy (CTE) and progressive supranuclear palsy (PSP).We explore the evolving landscape of neuropathologies, breaking down how conditions like Alzheimer's can be understood beyond just plaques and tangles, and examining what tauopathies mean for both patients and medical trainees. Dr. Crary also discusses the impact of concussions in sport, the role of Artificial Intelligence in brain research, and the challenges of bias in medical datasets.Whether you're a medical student, researcher, or simply curious about the brain, this episode offers a deep yet accessible look at the intersection of science, medicine, and technology in understanding neurodegeneration.For more on Dr. Crary's work, visit www.crarylab.org.If you want to support Doctor's Inn, here are some easy ways:1. Leave a rating! We welcome all feedback!2. Visit our website at www.doctorsinnpodcast.com to gain access to in-depth resources and our YouTube channel at Doctor's Inn Podcast to watch short engaging animated videos3. Follow our socials @doctorsinnpodcast

Ann visits with Raj Sinha, MD, PhD, and talks with Tanner Carlson about the AdventHealth Shine the Light event. Finally, we get Act Locally Live from Elizabeth Riley. Learn more about your ad choices. Visit megaphone.fm/adchoices

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Ken Culver, MD, the director of Research and Clinical Affairs at ALK Positive Inc.  Drs Camidge and Culver discussed the highlights of Dr Culver's career, which has been shaped by clinical practice, research, industry leadership, and patient advocacy. They noted elements of ALK Positive that set it apart from other patient advocacy groups, including its being entirely created, funded, and led by patients with stage IV lung cancer and their caregivers. Culver explained how he collaborates with patients to expand treatment opportunities, meets with companies and universities worldwide, and helps stakeholders recognize both the unmet needs and financial incentives for developing therapies for ALK-positive lung cancer. Culver detailed his path to the oncology field, which began with an intention to practice as a community pediatrician in Iowa. This led him to pursue residency training in California, where he gained diverse clinical experience, particularly in HIV/AIDS at the height of the epidemic. His early research explored HIV transmission in children born to drug-using mothers, highlighting the immunosuppressive effect of drug abuse even in the absence of HIV. During his fellowship, he contributed to pioneering work in gene therapy. He also participated in research that laid the groundwork for tumor-directed therapies, which later influenced large-scale clinical trials. Eventually, Culver explained that transitioned to industry. At Novartis, he contributed to the development of important drugs and witnessed the transformative launch of imatinib (Gleevec), one of the first targeted cancer therapies. Alongside his professional work, Culver established the Foundation for Peace, a nonprofit providing medical and community support in the Dominican Republic, Haiti, and Kenya. This initiative, which began with a mission trip in 1989, has grown to involve hundreds of volunteers annually, offering both medical care and broader community services. In his current role with ALK Positive, Culver noted that he has leveraged patient-led advocacy to influence industry priorities, resulting in several new clinical trials for ALK-positive patients. His work emphasizes balancing discovery research with near-term clinical opportunities to directly benefit patients with cancer today. He also shared how he prioritizes tools to empower patients, such as clinical trial finders, and stressed the importance of having contingency plans before disease progression. Overall, this conversation highlights a career that reflects a consistent commitment to science, patient care, and global service, guided by both professional and humanitarian values.

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

Donna Vogel, MD, PhD, joins us this week to share her journey of recognizing that it was time for retirement and how she optimized her plan using her trademark discipline and scientific vigor to achieve the healthiest possible retirement from a physical, mental, and financial standpoint. This is Dr. Vogel's ninth appearance on the Faculty Factory Podcast, and we are immensely grateful for her selfless and relentless contributions to this community over the years since our 2019 inception. Among her career highlights, she served as Director of the Professional Development Office at Johns Hopkins Medicine and was the Program Director of the Reproductive Medicine grant portfolio at the National Institutes of Health (NIH). She is also a former Jeopardy! champion, having won four consecutive days and reaching the semifinals of the Tournament of Champions. The four pillars of retirement, according to Dr. Vogel, and discussed toward the end of this podcast, are as follows: Financial planning Health and general fitness Things you do for yourself Things you do for others “Above all, keep learning in retirement, as that overlaps with all four pillars and ties them all together. Never stop learning,” Dr. Vogel told us in the closing moments of today's show. Important Resources from Today's Chat Helping Medical Education Faculty Navigate a Post-Academic Landing Pad (Recent Academic Medicine editorial) New York Times article on retirement and mental health referenced by Dr. Vogel The Academy at Johns Hopkins for retired faculty Learning Ally Catch up on Dr. Vogel's Faculty Factory Appearances Networking in a Virtual Environment Applying for Funding, Top Ten Things to Know Be a Memorable Mentor Get That Paper off the Ground How to Turbocharge your Presentation Skills Overcoming Imposter Syndrome Professional Societies, Beyond Getting the Journal Time Management for Faculty Please make sure to listen to today's episode via the podcast player above; and listen to more podcast episodes here.

Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

In this episode Steven Zeiler, MD, PhD joins to discuss the promise of psychedelics for stroke healing. Dr. Zeiler is an associate professor and physician at Johns Hopkins School of Medicine specializing in cerebrovascular disease, including acute stroke therapy, prevention, and recovery. He is a lead investigator for a Rose Hill Life Sciences research trial, conducted in partnership with Johns Hopkins University, exploring the use of psilocybin-assisted therapy to enhance motor function in patients with neurological injuries. In this conversation, Dr. Zeiler explains that after a stroke, there is a natural but time-limited critical period during which the brain is highly plastic and capable of repairing motor function. His research, inspired by work on psychedelics reopening critical learning windows, shows in animal models that a single high dose of psychedelics combined with intensive rehabilitation can restore lost motor abilities even after recovery has plateaued. Throughout, Dr. Zeiler emphasizes that psilocybin itself doesn't heal the brain directly but creates a window of heightened neuroplasticity that, when paired with targeted therapy, may dramatically improve recovery outcomes for stroke survivors.   In this episode, you'll hear: What happens to patients during a stroke The critical period of stroke recovery and how psychedelics may reopen this opportunity Why conducting a safety and tolerability study of psilocybin for stroke patients is crucial What forms of deficits and recoveries Dr. Zeiler's study will measure  Dr. Zeiler's speculations on what integrating psychedelic treatments into stroke medicine could look like The importance of specialized interventions that take advantage of the critical recovery period   Quotes: “What has been a little forgotten about in a lot of stroke management situations is helping the person get over the deficits with which the stroke has left them. And if you can't move an arm, you can't move a leg, that's a big deal. And we are not quite as good at addressing some of those problems.” [5:11]  “[The potential of psychedelics for stroke recovery] is probably less about addressing the injury itself and more about helping the remaining parts of the brain turn on to address what's lost.” [7:36] “We're not suggesting that the psychedelic itself has some sort of magical property that would just repair the brain, but it primes the situation to allow that input that we then provide over the next many days, many weeks, to affect a recovery.” [13:31] “Imagine something as complicated as the brain going through a repair mechanism: could you imagine one molecule acting on one receptor being able to affect a recovery? I couldn't imagine that—it's too complicated a thing. And so having something like a mechanism of action that is acting through multiple pathways, I think has to be the case if we're going to affect something as complicated as brain repair.” [17:30]   Links: Dr. Zeiler on LinkedIn Super Room for Enriched Neurological Repair at Green Spring (SENRG) PHATHOM (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability)-Stroke Project Psychedelic Medicine Association Porangui

Looking to go molecule deep in atopic dermatitis? We've got just the expert. This week, we're joined by Dr. Christopher Bunick as he brings structural biology into the atopic dermatitis discourse. Listen in as he discusses cytokines, itch, and the new definition of “skin clearance.” Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Christopher Bunick, MD PhD is an Associate Professor of Dermatology at Yale School of Medicine in the Department of Dermatology. He specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at Yale School of Medicine. Chris' research has pioneered a new focus in dermatology on fundamental biochemistry and structural biology, particularly connecting the atomic resolution mechanisms of action of a therapeutic to its clinical performance and safety.   Sponsored by: LEO Pharma Visit LEO Pharma website for more information. 

In today's episode, we spoke with Scott Kopetz, MD, PhD, FACP, about the use of circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC). Dr Kopetz is the deputy chair for Translational Research and a professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine, as well as the leader of the Department of Cancer Center Support Grant in the GI Program, the TRACTION medical director in the Division of Therapeutics Discovery, and the associate vice president for Translational Integration at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kopetz discussed the high positive predictive value of ctDNA assays, which indicate disease presence when positive. He emphasized  clinical trials that have shown strong prognostic implications with this type of assay, as well as study findings that demonstrated that ctDNA results could reduce chemotherapy use without compromising efficacy. Additionally, he noted the potential significance of ongoing trials that are exploring the use of ctDNA to guide therapy. Overall, he explained that ctDNA testing is becoming a standard in clinical practice for colorectal cancer. 

What if everything you thought you knew about skincare, acne, anti-aging, and hair loss was either outdated (or just plain wrong?)In today's solo-hosted episode of The Fitness Stuff (for Normal People), Tony sits down with Carter Gottlieb (aka Eviba Carter): cosmetic chemist, MD/PhD candidate, Chief Product Officer at HelloSkin, and one of the most respected voices in the skincare science world.This is not your typical skincare episode. Carter brings rare depth and clarity to topics normally clouded by hype, influencer noise, and cosmetic marketing.Together, they explore:The truth about acne: what causes it, why most “quick fixes” make it worse, and what actually worksRetinoids vs. Retinol vs. Adapalene: the gold standards for acne and anti-agingThe real reason Korean and European sunscreens outperform American ones (and how to get them)Hair loss 101: minoxidil, finasteride, microneedling, and what makes hair look thickerWhy your skin is a mirror of internal health, and how lifestyle factors like stress, sleep, and diet matter more than you thinkThe skin barrier, slugging, in-clinic vs. at-home treatments, and what to skip entirelyThe future of skincare technology, and how HelloSkin is pushing it forwardAnd yes, the story behind Carter putting a microchip in his handWhether you're battling acne, trying to keep your skin healthy as you age, or just want to stop wasting money on the wrong products, this episode cuts through the BS and gets straight to what actually works, backed by science, not hype.Carter's Recommendations & WebsiteCarter's Recommended Korean Sunscreen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Legion Athletics⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LABOR DAY SALE!!BOGO 50% off for your first order + 2X points on every order after thatuse code “FSPOD” at checkout⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for Fitness Stuff PREMIUM here!!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ALL of our complete 12-week training programsBonus episodes every FridayJust $5 /monthTimestamps:(2:05) Day-of Acne Fixes(15:18) Skin-care vs. Acne-care(37:00) Skin-care + Anti-aging Essentials(48:00) Korean Sunscreen vs. USA Sunscreen(51:10) Tanning Peptides(01:01:24) Carotenoids Supplements For Skin Glow + UV Protection(01:14:44) Skin Care Routine Fundamentals(01:29:00) Slugging(01:39:30) Rise And Fall of Eviba Skincare(01:53:25) Hair Loss + Thicker Hair Essentials

In this special edition episode, recorded live at the ASCO Annual Meeting, hosts Shikha Jain, MD, and Edward Kim, MD, honor Healio's 2025 Disruptive Innovators for their positive disruption in the field of hematology/oncology, and for pushing the status quo to improve clinical practice.  •    Welcome to the fourth annual Healio Disruptive Innovator Awards in hematology/oncology. 1:00 •    VK Gadi, MD PhD, presents the Health Equity Award. 3:56 •    The Health Equity Award winner, Ana Velázquez Mañana, MD, makes a speech. 6:00 •    Morgan Collier presents the Woman Disruptor of the Year Award. 7:38 •    Betty S. Pace, MD, accepts the Woman Disruptor of the Year Award. 9:19 •    The Social Media Influencer Award, presented by Eleonora Teplinsky, MD. 11:53 •    Amani Jambhekar, MD, also known as @ajvictorymd on Instagram and TikTok, accepts the Social Media Influencer Award. 13:13 •    Brenda M. Nevidjon, MSN, RN, FAAN, presents the Advanced Practice Trailblazer Award. 14:40 •    Ashley Leak Bryant, PhD, RN, OCN, FAAN, delivers her acceptance speech for the Advanced Practice Trailblazer Award. 16:19 •    Kamal Jethwani, MD, MPH, presents the Patient Voice Award. 18:44 •    Founder Kimberly Richardson, MA, accepts the Patient Voice Award for the Black Cancer Collaborative. 20:44 •    Healio's chief content officer, Joan-Marie Stiglich, ELS, presents the NextGen Disruptor Award to Nazli Dizman, MD. 22:22 •    The Clinical Innovation Award goes to UNC Lineberger Comprehensive Cancer Center for their at-home symptom reporting, led by Ethan Basch, MD, MSc. 24:18 •    Hope S. Rugo, MD, wins the Lifetime Disruptor Award. 26:48 •    The Industry Breakthrough Award goes to Breyanzi (lisocabtagene maraleucel, or liso-cel) from Bristol Myers Squibb. 30:57 •    On behalf of Bristol Myers Squibb, Amy Corrao, MSN, NP-C, accepts the Industry Breakthrough Award. 32:33 •    Thanks to all of the winners, nominees and sponsors! 35:39 •    Thanks for listening. 36:21 We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Read the full coverage from Healio's Disruptive Innovators here.

In today's episode, supported by Nuvation Bio, we spoke with Joel Neal, MD, PhD, and Christian Rolfo, MD, PhD, about the FDA approval of taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic, ROS1-positive non–small cell lung cancer (NSCLC). Dr Neal is a professor of medicine in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Rolfo is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State University in Columbus. In our conversation, Drs Neal and Rolfo discussed the significance of this approval, key data from the pivotal phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, and taletrectinib's current role in the NSCLC treatment paradigm.

In today's episode, supported by Boehringer Ingelheim, we spoke with Ticiana Leal, MD, and Misako Nagasaka, MD, PhD, about the FDA approval of zongertinib (Hernexeos) for previously treated patients with HER2 TKD–mutant advanced non–small cell lung cancer (NSCLC). Dr Leal is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University. Dr Nagasaka is an associate professor of medicine in the Division of Hematology and Oncology at the University of California, Irvine (UCI) School of Medicine; as well as a medical oncologist at UCI Health. In our conversation, Drs Leal and Nagasaka discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1 Beamion LUNG-1 trial (NCT04886804), and where zongertinib currently fits into the NSCLC treatment paradigm.

In today's episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.  In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL. 

Your hairbrush is collecting more strands than your scalp these days. You've tried the shampoos, thesupplements, the ‘miracle cures'—but nothing works. What if the real solution isn't in a bottle… but inunderstanding why your hair is falling out in the first place? This Hair Loss Awareness Month, we'recutting through the hype and revealing what actually stops shedding and regrows hair—backed byscience. From FDA-approved treatments to nature's hidden remedies this is your guide to taking backyour hair—and your confidence.Special Guest: Dr. Ken Washenik, MD PHD and Chief Medical Officer of Bosley HairRestoration

What if your dinner could work as well as your prescription? In this episode, I'm joined again by Dr. Mary Sco., MD-PhD in Nutrition Sciences, to break down head-to-head comparisons of diet and lifestyle changes versus medications. From cholesterol and blood pressure to migraines, diabetes, and even mental health, we look at the research on when food can match—or even outperform—pharmaceuticals, and when prescriptions are still the best choice. LINKS The Truth Behind Seed Oils with Dr Mary Sco | https://bit.ly/4fIk4Cr  Molly's ‘Beyond LDL' podcast with Dr Lavie | https://bit.ly/4mk3Sd1 Fish Oil: A Master Class with Dr Lavie | https://bit.ly/46X4KzH Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

In this episode, we speak with Prof. Johannes Gojo, MD, PhD, one of the world's foremost experts in pediatric neuro-oncology. Dr. Gojo shares groundbreaking research into ETMR and ATRT brain tumors, the promise of liquid biopsies, and how international collaboration through CARE for RARE (established by Solving Kids' Cancer) is transforming outcomes for children with rare brain tumors.We also highlight a newly funded research project, supported by multiple organizations including Gold Ribbon Kids, that aims to deliver precision medicine breakthroughs for some of the most aggressive childhood cancers.Topics CoveredWhy ETMR and ATRT are so difficult to treatThe role of liquid biopsies in monitoring and guiding therapyHow CARE for RARE and global consortia accelerate progressThe impact of family-driven advocacy on scientific discoveryThe hope behind newly funded research initiatives

Camidge and Lee discussed Lee's professional journey and personal insights gained from years of working at the intersection of clinical research and patient care. 

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

  Interviewees: Tom Pisano, MD PhD and Laura Ashley Stein, MD, MS, Ed. Interviewer: Lisa Meeks, PhD, MA Description: In Episode 111, Dr. Lisa Meeks talks with Dr. Tom Pisano (former Penn neurology resident; now neuro-hospital medicine and neuro-immunology fellow) and Dr. Laura Stein (Adult Neurology Program Director at Penn) about building an accessible neurology residency for a physician who uses a wheelchair—and how trust, planning, and culture made it work. Together, they trace Tom's match-day disclosure strategy and “find-your-people” approach, an accessibility walk-through with tape measures and ADA checks, and the practical creativity of equivalent rotations when sites differ in accessibility. They also unpack a real barrier—a security policy that blocked ED entry during stroke alerts—and how reframing access as patient safety moved the system. Listeners will hear candid advice for residents (hold onto your “why,” communicate early, invite teaching adaptations) and for program directors (start with goals, not habits; assume success; apply the same creativity you offer patients to your trainees). This episode accompanies a written case study and a Mini Grand Rounds conversation in Learn at ACGME. Part of the ACGME/DWDI Disability Resource Hub, supported by the Josiah Macy Jr. Foundation Catalyst Award, it's a practical guide for PDs, residents, and anyone committed to equitable clinical training.   Transcript: https://docs.google.com/document/d/1xB_Cp8EiekJ9ExUZLP61EvE-0y4HUv22LuRp0D6uNB0/edit?usp=sharing Key words: Medical education, physical disability, disability research, residency, accommodations, wheelchair, SCI, medical technology, residency, neurology, program director, GME, GME Policy Bio: Laura Stein I have been involved in the Neurology Residency Program since 2018, and Director of the program since 2024. I teach residents on multiple inpatient services as well as in outpatient continuity clinic and stroke clinics. I also lead didactic sessions and workshops for resident onboarding and in our resident lecture series. I am particularly interested in expanding resident exposure to structured experiences in medical education and quality improvement and currently mentor multiple residents per year in medical education and quality improvement projects. In 2020, I was honored to receive the University of Pennsylvania Neurology Residents teaching award. I received my masters in medical education from the University of Pennsylvania in 2018. I have been a member of the American Academy of Neurology (AAN) Residency-In-Training Examination Committee since 2019. I have also been a member of the American Heart Association (AHA) Stroke Professional Education Committee since 2016 and currently serve as the Vice Chair of this committee. Clinically, I function predominantly as a neurohospitalist and attend on the stroke inpatient and consult services, the neurology ward service, and the PPMC consult service. I am dedicated to ensuring delivery of high-quality neurologic care across our system and currently am the physician co-lead for our neurovascular disease team, which spans our six-hospital network, as well as our HUP inpatient neurology unit-based quality improvement team. Tom Pisano I enjoy weekend bike rides with my wife, followed by trying out a new restaurant. When traveling, if possible, I always try to get in some monoskiing or scuba diving. I would also consider myself a (very) mildly competitive board gamer. I will be pursuing a combined neurohospitalist/neuroimmunology fellowship to develop expertise in myelopathies. My research includes brain-computer interfaces, especially of the spinal cord. Producer:  Lisa Meeks Follow Us: X: @DocsWith Instagram: @DocsWithDisabilities Linked In: https://www.linkedin.com/company/docs-with-disabilities-initiative Resources:  Disability Resource Hub: https://dl.acgme.org/pages/disability-resource-hub Case Studies in Disability Resource Hub: https://dl.acgme.org/pages/disability-resource-hub#case_studies UME to GME Toolkit:  https://dl.acgme.org/pages/disability-resource-hub-transitions-toolkit-introduction Policy Toolkit: https://dl.acgme.org/pages/disability-resource-hub-policy-toolkit Disability in Graduate Medical Education Program:  https://www.docswithdisabilities.org/digme   Link to Case Study: Coming Soon!              

In this episode, Raval welcomed David A. Frank, MD, PhD, FACP, who is director of the Division of Hematology and a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center.

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr García-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes for this patient population. 

In this episode, Sam Ashoo, MD interviews Christina Shenvi, MD, PhD, MBA about ways to manage your day and keep distraction at bay.Introduction to Dr. Christina ShenviWhy Focus and Time Management MatterExperiences coaching medical students and professionalsThe importance of managing mind, time, and attentionApplicability to both career and personal lifeFramework for FocusThree-step framework: Prioritize, Strategize, FocusExplanation of prioritizationMapping personal and professional activities to prioritiesDeep Work vs. Shallow WorkDefining deep work and shallow workStrategies for categorizing and scheduling tasksTime-blocking and protecting focus timeOvercoming DistractionThe psychology of distraction and procrastinationThe impact of digital devices and social media on attentionThe variable reward system of social media and its addictive natureStrategies to Improve FocusClearing mental, physical, and digital environmentsThe importance of a distraction-free workspaceSystems for capturing and organizing tasksThe Pomodoro method and using time pressureBuilding a Personal SystemExperimenting with different task management toolsAdapting systems to personal needs and preferencesDaily Practice and Training FocusReviewing and updating task lists dailyChunking email and shallow work to specific timesTraining the brain to focus like a muscleSpecial considerations for people with ADHDResources and ContactDr. Shenvi's website and online course (timeforyourlife.org)Invitation to connect for coaching or further learningFor more about Christina Shenvi : https://timeforyourlife.org/

In our exclusive interview, Dr Blanco discussed the significance of this regulatory milestone for a population that has historically lacked effective medical options. He reviewed the pivotal phase 2b ReNeu clinial trial (NCT03962543)that supported this decision, which enrolled both adult and pediatric patients with nonresectable PNs and evaluated clinical and radiologic response rates. Dr Blanco detailed the study's findings, including overall response rates of 41% and 52% in the adult and pediatric populations, respectively; meaningful reductions in tumor volume; improvements in patient-reported pain and quality of life; and the favorable safety profile characterized primarily by dermatologic and gastrointestinal adverse effects.

In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect on tolerability. Dr Élez also highlighted the importance of tailoring immunotherapy strategies based on patient characteristics and treatment goals and reflected on the nuances of sequencing single‑agent vs combination checkpoint blockade.

Mauro Zappaterra obtained his MD and PhD from Harvard Medical School. He is board-certified in physical medicine and rehabilitation with a focus on optimizing human performance, increasing awareness and decreasing suffering. He has been practicing mindfulness since 1998, and teaching mindfulness to patients with chronic pain since 2018, and he is the Director of Multidisciplinary Care at Synovation Medical Group.  He has led the Awakening Awareness Program and Inward Inquiry for the Emerging Sciences Foundation which can be found on YouTube.  He has published numerous scientific papers and medical book chapters on the cerebrospinal fluid, disability, and pain management. He has also published "I Am", "All One", and "All Love" which are three books exploring topics of awareness, primarily for kids, but really for people of all ages.  He has also published "Close Your Eyes, What Do You See?" with his son, which is a story about imagination and intention.  And he also published "A is for Awarness: A Consciousness Expanding Alphabet", a new alphabet book.  These can all be found on Amazon. He continues to create programs to help patients with chronic pain and investigate the cerebrospinal fluid and integrate new research to evolve the hypothesis of The Cerebrospinal Fluid and I Am. SHOWNOTES:

Uniting scientists and harnessing the power of the immune system to fight disease is at the heart of the Center for Human Immunobiology (CHI). Stephanie Eisenbarth, MD, PhD, leads the center, and she is also the chief of Allergy and Immunology in the Department of Medicine.   Since this episode was first recorded in fall 2022, Eisenbarth's team has launched a clinical trial to study a new treatment for food allergy. She has also brought together more than 150 trainees and faculty through the CHI. Here, she discusses the variety of immunology research taking place within the center and the continued work to discover and translate innovative science into cures for immune-related diseases. 

In today's episode, we had the pleasure of speaking with Martin F. Dietrich, MD, PhD, about updates and best practices for HER2 and MET immunohistochemistry (IHC) testing for patients with non–small cell lung cancer (NSCLC). Dr Dietrich is a medical oncologist at Cancer Care Centers of Brevard in Rockledge, Florida; as well as an assistant professor of internal medicine at the University of Central Florida in Orlando.  In our exclusive interview, Dr Dietrich discussed the rationale for testing for these mutations in patients with NSCLC, standard practices for implementing these tests in the clinic, and when testing may be appropriate at disease progression. 

In this conversation, I sit down with Nick to unpack the deeper science behind GLP-1s and metabolic health. We explore how compounds like Tirzepatide and GLP-1 agonists go beyond weight loss, influencing everything from cardiovascular elasticity and neuroinflammation to mood, cognition, and gut-brain signaling. We also discuss lesser-known drivers of real change, like adiponectin, MPO, and the surprising effects of statins on inflammation.But the conversation doesn't stop with human health. We dive into the behavioral power of the microbiome, how dogs might reduce childhood allergies, and whether AI can actually translate what your pet is thinking. If you're curious about fat loss, brain health, and the future of metabolic science, this episode offers a perspective you won't find anywhere else.*Chapters:*0:00 – Meet Dr. Nick: From Patient to Pioneer06:50 – The Problem with "Evidence-Based Medicine"10:15 – Why Nick Left the Medical System13:10 – Can YouTube Have a Bigger Impact Than Hospitals?16:30 – What Is Metabolic Health & Why Does It Matter?19:00 – Mental Health, Depression & Metabolism24:15 – Brain Hacks That Actually Work40:00 – Improving Metabolic Flexibility Naturally46:00 – Gut-Brain Connection & Fiber Myths*Nick's Socials + Website*IG: https://www.linkedin.com/in/nicknorwitz/Youtube channel: https://www.youtube.com/channel/UCLTZUJSEulehPtF_ytFiU_AWebsite: https://www.nicknorwitz.com*Kayla's Socials + Website*Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevityWebsite: https://www.kaylabarnes.comFollow Her Female Protocol: https://www.protocol.kaylabarnes.comBecome a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

If you've been searching for a roadmap to true physician financial freedom, Dr. Christopher H. Loo, MD-PhD, shares how he quit medicine and built lasting wealth through strategic investing, entrepreneurship, and mindset shifts.In this episode of Permission to Kick Ass, we unpack what it means to escape burnout and reclaim your time, money, and energy outside traditional medical practice. Dr. Loo opens up about his journey from physician to multimillionaire investor, offering real-world advice that speaks directly to those looking for:financial independence for doctorsleaving medicine for entrepreneurshippassive income for physiciansburnout solutions for healthcare professionalsinvestment strategies for doctors

"I have had quite some reactions to the article [on their psychoanalyses]. I was also telling Mauro and my colleagues that out of quite a number of articles I've published on maybe more pressing issues in the field of cancer research, for example, brain tumor research that I've spent quite some time with, I think it's actually the article [on psychoanalysis] that probably prompted the most reactions, at least in my personal surroundings, and the reactions have been overwhelmingly positive. So colleagues are very interested. They often ask questions about psychoanalysis, quite specifically, how it works, how it contributed, and also complemented the article in the sense that it was something that was quite outside of the box, so outside of the typical surgical publication.” - FV   "How can we reach surgeons? How can we make this interesting and attractive for them to even consider? I think most surgeons will be very performance-driven people, and I think that it goes hand in hand that that type of person will seek ways to improve themselves, but probably more in a technical way. Let's say they want to get faster in their operations. They want to get more skillful. They want to do more complicated surgeries. So there's a lot about self improvement in that you exercise until you master something. And I think that analogy with sports was our way of saying, hey, you know, this is actually pretty cool. You can compare yourself to  professional athletes, in terms of self improvement, and this is actually one way you can get there, how you can improve. At the same time, it was also important for us to acknowledge that it's not for everyone so we also mentioned alternatives, of course." - MV   Episode Description: Mauro and Flavio begin by describing the encouragement they received from their father to pursue personal analysis "to explore our unconscious minds for a lighter life and less emotional baggage." They share their psychoanalytic journeys and give examples of how their greater capacity to reflect instead of react has led to improved surgical patient outcomes. They also describe collegial tensions that were more clearly addressed through their ability to authentically know how they felt. They recommend that like elite athletes who have sports psychologists to address obstacles to their performances, so might surgeons appreciate the utility of psychoanalysis and other measures to improve their clinical attunement. Mauro concludes "Everyone has their baggage - don't be afraid to look at it and to understand what's going on. It's worth it."   Our Guests: Flavio Vasella, MD PhD, is a junior attending neurosurgeon at the University Hospital Zurich, with a clinical and research focus on neurosurgical oncology. He earned his PhD in Molecular Life Sciences at the University of Zurich, where his research explored genome editing strategies in primary brain tumors. His primary academic interests include translational and clinical neuro-oncology as well as surgical education.   Mauro Vasella, MD, is a board-certified plastic surgeon with multiple years of clinical experience specializing in reconstructive surgery. He is affiliated with the University Hospital Zurich in Switzerland and the Royal Melbourne Hospital in Australia and has held positions as a fellow and attending surgeon. His practice and research field focuses on regenerative-reconstructive surgery and burn injuries.   Recommended Readings: FV - Paul Kalanithi – When Breath Becomes Air This memoir by a neurosurgeon-turned-patient is a poetic and piercing meditation on mortality, identity, and the transition from doctor to patient. It explores the tension between the analytical and emotional mind (somewhat paralleling the internal work of psychoanalysis) and offers profound insight into the humanity at the core of medical practice. Bill George – True North: Discover Your Authentic Leadership This book presents a leadership philosophy rooted in self-inquiry, values, and life stories. True North emphasizes that effective leadership comes from understanding your life narrative and using that insight to lead with integrity and resilience. True North challenges leaders to cultivate authenticity by exploring their internal landscape. While the book focuses on leadership in a business context, it offers a compelling, practical perspective for medical professionals as well. Atul Gawande – Complications: A Surgeon's Notes on an Imperfect Science Gawande offers a candid look at the uncertainties, dilemmas, and emotional burdens of being a surgeon. His reflection on fallibility and decision-making underlines the importance of non-technical skills and the internal work required to become not just competent, but humanely attuned, in medicine. The impact of nontechnical skills on technical performance in surgery: a systematic review. Hull L, Arora S, Aggarwal R, Darzi A, Vincent C, Sevdalis N. J Am Coll Surg.2012  This systematic review analyzed 28 studies linking surgeons' non-technical skills—such as teamwork, situational awareness, and stress management to actual technical performance in the operating room. It found evidence that effective NTS positively affects outcomes, while fatigue and communication failures contribute to technical errors.   MV - The Art of Loving – Erich Fromm Realizing the simple but somehow not always obvious fact that before being able to truly love someone, one must truly find themselves loveworthy. This implies and demands introspection, as well as forgiveness towards yourself and others. Outliers: The Story of Success – Malcolm Gladwell To master something, one must invest a substantial amount of time and dedication – this is not only true for technical skills, but also non-technical skills. Personal growth is only possible if you invest time, such as undergoing a psychoanalysis or similar. The Checklist Manifesto – Atul Gawande While the checklist itself is very technical, the way it was conceived and its effect was and still is rather non-technical. It is a question of putting your ego aside and truly focusing on areas which you can improve.